Attovia Therapeutics, Inc. Research and Development Expense
Attovia Therapeutics, Inc. (ATTO) reported Research and Development Expense of $18.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-02.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-02
- Attovia Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $18.95M, a 39.43% increase year-over-year.
- Attovia Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $13.59M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $18.95M 10-Q · filed 2026-09-02 | $35.69M 10-Q · filed 2026-09-02 |
| 2025-06-30 | $13.59M 10-Q · filed 2026-09-02 | $25.44M 10-Q · filed 2026-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |